Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (844)

1

Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2024

von Harvey-Jones, E. | Raghunandan, M. | Robbez-Masson, L. | +36

2

DePARylation is critical for S phase progression and cell survival

enthalten in: eLife | 2024

von Nie, L. | Wang, C. | Huang, M. | +10

UpdateOf: bioRxiv. 2024 Feb 02;:. - PMID 37577639

3

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer

enthalten in: Cancer medicine | 2024

von Uekusa, R. | Yokoi, A. | Watanabe, E. | +9

4

Current post-surgical treatment strategies in first-line ovarian cancer

enthalten in: Bulletin du cancer | 2024

von Ouali, K. | Michels, J. | Blanc-Durand, F. | +9

5

Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction : A Case Report

enthalten in: In vivo (Athens, Greece) | 2024

von Endo, Y. | Kamo, N. | Kato, A. | +5

6

Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy

enthalten in: Advances in therapy | 2024

von Rognoni, C. | Lorusso, D. | Costa, F. | +1

7

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers

enthalten in: Cell reports. Medicine | 2024

von Alruwaili, M. | Zonneville, J. | Naranjo, M. | +11

8

NRG-GY012 : Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

enthalten in: Cancer | 2024

von Rimel, B. | Enserro, D. | Bender, D. | +10

9

Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor

enthalten in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | 2024

von Teng, Q. | Lei, Z. | Wang, J. | +9

10

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit : Focus in Ovarian Cancer

enthalten in: International journal of molecular sciences | 2024

von Bailey, M. | Morand, S. | Royfman, R. | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[85]